MORC4

MORC4 is a nuclear ATPase that regulates chromatin accessibility, nuclear body formation, and transcriptional programs through cooperative DNA binding and nucleosome remodeling. Its ATPase activity is stimulated by DNA engagement through both its ATPase and CW zinc-finger domains; structurally, the CW domain positions DNA-binding and histone-contact surfaces on opposite faces, enabling MORC4 to bind nucleosome core particles, enhance DNA wrapping around histones, and occlude transcription factor access (PMID:33122719). In cells, MORC4 drives nuclear body formation and S-phase progression in a CW- and ATPase-dependent manner, and it modulates transcription by cooperating with STAT3 to activate the MID2 promoter and with PCGF1 to repress CDKN1A (PMID:33122719, PMID:32764967, PMID:36932196). MORC4 protein levels are regulated post-translationally by HECW2-mediated ubiquitin-proteasome degradation and post-transcriptionally by miR-193b-3p and miR-338-3p (PMID:36932196, PMID:30320920, PMID:31908485).

1. 2007 Low

   Initial characterization established the domain architecture of MORC4 — including its ATPase, CW zinc-finger, nuclear localization signals, and coiled-coil regions — providing the first framework for predicting its nuclear function.

   Evidence Sequence analysis and antibody detection in cell lines

   PMID:17608765

   Open questions at the time

   • No functional assays of any domain were performed
   • Nuclear localization inferred from sequence motifs, not imaging
   • Enzymatic activity of the predicted ATPase domain untested
2. 2018 Medium

   The identification of miR-193b-3p as a direct negative regulator of MORC4 mRNA established that MORC4 expression is subject to microRNA-mediated post-transcriptional control and linked MORC4 levels to breast cancer cell survival.

   Evidence Dual-luciferase reporter assay confirming 3′ UTR targeting, Western blot, and functional knockdown in breast cancer cell lines

   PMID:30320920

   Open questions at the time

   • Downstream effectors of MORC4 in the pro-survival phenotype were not identified
   • In vivo validation of miR-193b-3p–MORC4 axis absent
3. 2019 Medium

   A second microRNA, miR-338-3p, was shown to directly target MORC4, reinforcing the post-transcriptional regulatory layer and connecting MORC4 downregulation to suppressed breast cancer migration and invasion.

   Evidence Luciferase reporter assay and RNA immunoprecipitation confirming direct binding, functional rescue in breast cancer cells

   PMID:31908485

   Open questions at the time

   • Relative contributions of miR-193b-3p versus miR-338-3p to endogenous MORC4 regulation unclear
   • The pharmacological agent (baicalin) used to upregulate the miRNA adds confounding variables
4. 2020 High

   Structural and biochemical work resolved how MORC4 functions as a DNA-stimulated ATPase: the crystal structure of the ATPase-CW cassette revealed cooperative DNA binding by both domains, and nucleosome core particle assays showed MORC4 enhances histone–DNA wrapping while occluding transcription factor binding, establishing its chromatin-remodeling mechanism.

   Evidence Crystal structure determination, enzymatic ATPase assays, mutagenesis, and nucleosome core particle binding assays

   PMID:33122719

   Open questions at the time

   • Genomic targets of MORC4's nucleosome-remodeling activity in vivo are unknown
   • Whether MORC4 acts catalytically (turnover on multiple nucleosomes) or stoichiometrically is unresolved
5. 2020 High

   Cell-based studies demonstrated that MORC4 drives nuclear body formation and S-phase progression through its CW domain and ATPase catalytic activity, linking the in vitro biochemistry to defined cellular phenotypes.

   Evidence CW and catalytic-dead mutant analysis, nuclear body imaging, cell cycle analysis

   PMID:33122719

   Open questions at the time

   • Composition of MORC4-containing nuclear bodies is uncharacterized
   • Mechanism connecting nucleosome remodeling to S-phase progression is not delineated
6. 2020 Medium

   MORC4 was shown to physically interact with STAT3 and co-occupy the MID2 promoter, establishing a transcriptional co-activator function that promotes chemoresistance in breast cancer cells.

   Evidence Co-immunoprecipitation, ChIP-qPCR, dual-luciferase reporter assay, and siRNA knockdown in luminal A/B breast cancer cells

   PMID:32764967

   Open questions at the time

   • Whether MORC4's ATPase or nucleosome-remodeling activity is required for STAT3 co-activation is untested
   • Generality of MORC4–STAT3 cooperation beyond the MID2 locus unknown
7. 2023 Medium

   The discovery that MORC4 interacts with PCGF1 to repress CDKN1A transcription established a repressive transcriptional partnership and revealed HECW2-mediated ubiquitin-proteasome degradation as a mechanism controlling MORC4 protein turnover.

   Evidence Co-immunoprecipitation, luciferase reporter assay, proteasome inhibitor and ubiquitination assays in colorectal cancer cells

   PMID:36932196

   Open questions at the time

   • HECW2-mediated degradation demonstrated by a single lab without independent confirmation
   • Ubiquitination sites on MORC4 not mapped
   • Whether PCGF1 interaction is direct or within a larger Polycomb complex is unresolved
8. 2025 Low

   A hepatocyte knockdown/overexpression study linked MORC4 to regulation of hepatic lipid metabolism, revealing effects on cholesterol synthesis (HMGCR) and lipid uptake/hydrolysis genes, broadening MORC4's functional scope beyond cancer biology.

   Evidence siRNA knockdown and overexpression in hepatocytes with TC/TG assays and gene expression profiling

   PMID:40606021

   Open questions at the time

   • No direct molecular mechanism connecting MORC4 chromatin activity to lipid gene regulation
   • Single-lab study without in vivo genetic confirmation in conditional knockout models
   • Whether MORC4 acts at lipid-gene promoters directly or via intermediary factors is unknown

• Genome-wide identification of MORC4's chromatin targets, the composition of MORC4 nuclear bodies, and the structural basis for its transcriptional partner selectivity (STAT3 vs. PCGF1) remain unresolved.
• No genome-wide ChIP-seq or CUT&RUN map of MORC4 occupancy exists
• Proteomic characterization of MORC4 nuclear bodies is lacking
• Structural basis for selective engagement with activating (STAT3) versus repressive (PCGF1) partners unknown